House committee weighs drug pricing proposals

Endpoints News, February 14, 2019
by Michael Mezher, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Mark Miller, executive vice president of health care at Arnold Ventures, told the committee that moving to a flat fee-per-prescription model for Medicare Part B could help to curb some spending. Both…

Read More

Can California Beat The Federal Government In Lowering Drug Prices?

Kaiser Health News, February 14, 2019
By Samantha Young, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Lawmakers face an array of challenges that make reform hard, such as secretive drug pricing and the political influence of the pharmaceutical industry, one of the most powerful lobbies in the country, said Rachel Sachs, an associate…

Read More

Sanders to Gables pharma firm: Why are you charging $375,000 for life-saving drug?

Miami Herald, February 6, 2019
by Rob Wile, quoting W. Nicholson Price (Academic Fellow Alumnus)

From the article: "Nicholson Price, an assistant professor at the University of Michigan who specializes in law surrounding innovation in the life sciences, said Catalyst would likely counter by saying it was responsible for spending the money to…

Read More

Can You Sue An Algorithm For Malpractice?

Forbes AI, February 11, 2019
by Forbes AI, interviewing W. Nicholson Price (Academic Fellow Alumnus)

From the article: "What’s in the box? The “black box,” that is. Increasingly, doctors are relying on sophisticated, and at times inscrutable, algorithms to make healthcare recommendations—a practice dubbed “black…

Read More

How Trump’s Latest Plan to Cut Drug Prices Will Affect You

New York Times, February 5, 2019
By Katie Thomas and Reed Abelson, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "The Trump administration says that a lot will depend on how companies react. If the plan takes effect next year, it could cost the government an extra $2.8 billion to $13.5 billion that same year. But…

Read More

Trump wants to slash drug rebate deals. Will it make a difference?

ABC News, February 4, 2019
by Jay Hancock, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "In any event, it’s hardly a pure win for seniors or patients in general. Consumers are unlikely to collect the full benefit of eliminated rebates. At the same time, the change would produce…

Read More

The Fight To Lower Soaring Drug Prices Turns Bitter Between States And The Feds

Huffington Post, February 4, 2019
By Michael Ollove, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "According to the National Institute on Money and Politics, a nonprofit that collects campaign finance data, the pharmaceutical industry in 2018 contributed nearly $19 million to state campaigns, and $56 million to federal ones. …

Read More

Winners And Losers Under Bold Trump Plan To Slash Drug Rebate Deals

Kaiser Health News, February 1, 2019
By Jay Hancock, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "In any event, it’s hardly a pure win for seniors or patients in general. Consumers are unlikely to collect the full benefit of eliminated rebates. At the same time, the change would produce…

Read More

The rebate rule is here

POLITICO Pulse, February 1, 2019
by Dan Diamond, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "Pharmacy benefit managers are likely to fight efforts to change the kickback exemption, which has been in place since Medicare Part D’s inception, said Sean Dickson of Pew Charitable Trusts. House…

Read More

Trump Administration Releases Long-Awaited Drug Rebate Proposal

HealthAffairs, February 1, 2019
by Rachel Sachs (Academic Fellow Alumna)

From the article: "Yesterday, the Trump Administration released a proposed rule which aims to eliminate rebates from pharmaceutical companies to pharmacy benefit managers (PBMs) in Medicare Part D and in Medicaid managed care organizations.…

Read More

Trump proposal would upend drug industry by overhauling rebates in Medicare

CNN, January 31, 2019
By Tami Luhby, quoting Rachel Sachs (Academic Fellow Alumna)

From the article: "The Trump administration unveiled a proposal Thursday that could radically change the way many drugs are priced and paid for in Medicare and Medicaid. The plan calls for effectively banning drug…

Read More

Infertile woman is pregnant with a ‘three-parent baby’ in first ever clinical trial

Daily Mail , January 25, 2019
by Mia De Graaf, quoting I. Glenn Cohen (Faculty Director)

From the article: "I. Glenn Cohen, a Harvard health law professor, warned American parents may well seek the treatment elsewhere, and it won't be clear how many three-parent babies are in the country. 'There is simply no way for any country…

Read More

Pregnancy reported in the first known trial of ‘three-person IVF’ for infertility

STAT, January 24, 2019
by Emily Mullin, quoting I. Glenn Cohen (Faculty Director)

From the article: "I. Glenn Cohen, a Harvard health law professor, said this new trial, as well as Zhang’s travel to Mexico for mitochondrial replacement therapy, may put pressure on the U.S. and other countries to change their policies for…

Read More

Congress has 7 big ideas to cut drug prices. Here’s how they work.

Vox, January 17, 2019
by Dylan Scott, quoting Rachel Sachs

From the article: "One irony of the ongoing drug prices debate, says Rachel Sachs, an associate professor at Washington University in St. Louis, is that the drug industry opposition to more modest proposals like this, targeted to particular bad actors…

Read More

Democrats examine drug prices, a first step in Congress’ path to cut prescription costs

USA Today, January 14, 2019
by Maureen Gropps, quoting Rachel Sachs

From the article: "Republican Sen. Chuck Grassley, the new chairman of the Senate Finance Committee, has said he will try to find solutions. 'It’s one of the top concerns I hear from Iowans,' Grassley recently…

Read More

Grassley is not pharma’s worst nightmare

Axios Vitals, January 14, 2019
by Caitlin Owens, quoting Rachel Sachs

From the article: "What he's saying: In an interview with my colleague Jonathan Swan and me, Grassley made clear he is no radical when it comes to pharma. The 3 bills at the center of his…

Read More

Petrie-Flom Center Seeks RA for Project on Drug Pricing

Petrie-Flom Center, Applications due January 25!

Call for Applications: Research Assistant, Drug Pricing in the U.S. and Globally The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School seeks a Research Assistant to support the creation of a white paper on drug pricing policies in the United States…

Read More

Congress is about to renew its ban on creating CRISPR babies in the US

MIT Technology Review, January 10, 2019
by Antonio Regalado, quoting I. Glenn Cohen (Faculty Director)

From the article: "By blocking any-and-all DNA changes to an embryo, I. Glenn Cohen, a professor at Harvard Law School, says American legislation has taken a "meat axe" approach when what's needed is a "scalpel" to separate good uses…

Read More

Perspectives on Gene Editing

Harvard Gazette, January 9, 2019
by Mary Todd Bergman, quoting I. Glenn Cohen (Faculty Director)

From the article: "Progress in this field has been so rapid that the dialogue around potential ethical, societal, and safety issues is scrambling to catch up. This disconnect was brought into stark relief at the Second…

Read More

House Democrats defend Obamacare as courts weigh in

USA Today, January 9, 2019
by Maureen Groppe, quoting Rachel Sachs

From the article: "Following through on Trump’s promise to reduce the cost of prescription drugs, the administration rolled out various proposals that analyst Rachel Sachs of Washington University in St. Louis said range from radical to more…

Read More